Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05212272 · ClinicalTrials.gov registry record · NA
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
A NA study of High Grade Glioma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05212272 is a NA study of High Grade Glioma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05212272, a NA study of High Grade Glioma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Conditions Studied
Interventions
- PROCEDURE PET-MRI Brain Scan
- DIAGNOSTIC_TEST Blood draw
- BEHAVIORAL Memory testing
- PROCEDURE Optional lumbar puncture for cerebrospinal fluid collection
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05212272
The ClinicalTrials.gov registry entry for NCT05212272 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (75% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 4 interventions - of which PET-MRI Brain Scan is the first listed.
NCT05212272 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05212272 about?
NCT05212272 is a clinical study titled "MRI in High-Grade Glioma Patients Undergoing Chemoradiation". The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET...
What is the current status of trial NCT05212272?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2022-09-02. Estimated completion is 2026-12.
What conditions does trial NCT05212272 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT05212272?
The interventions under investigation include: PET-MRI Brain Scan (PROCEDURE), Blood draw (DIAGNOSTIC_TEST), Memory testing (BEHAVIORAL), Optional lumbar puncture for cerebrospinal fluid collection (PROCEDURE).
Who is sponsoring clinical trial NCT05212272?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05212272 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.